Breast cancer Trials in Piraeus, Greece
Conditions / Breast cancer / Piraeus, Greece
Breast cancer has been the subject of sustained clinical investigation across multiple research sites.
14 total trials for this combination
Showing top 10 of 14 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01985724 | Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer | COMPLETED | PHASE3 |
| NCT05501886 | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00705315 | Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer | COMPLETED | PHASE1/PHASE2 |
| NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | RECRUITING | PHASE3 |
| NCT00453635 | Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients | TERMINATED | PHASE2 |
| NCT00431106 | Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer | COMPLETED | PHASE3 |
| NCT00431080 | Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer | COMPLETED | PHASE3 |
| NCT04873362 | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00429871 | Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer | COMPLETED | PHASE3 |
| NCT00615602 | Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer | COMPLETED | PHASE3 |